 we report financial results for the fourth quarter and full year of 2022 and provide an update on our operations and plans for 2023. 
 we also provide an update on our ongoing clinical activities including the launch of our first product for the treatment of advanced malignant pEComa and the initiation of a registration-directed trial in patients with solid tumors that have inactivating alterations in the mTOR pathway.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in 